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Abstract 
Background: Human antigen R (HuR) is an RNA binding protein that is overexpressed in many human cancers, includ-
ing lung cancer, and has been shown to regulate the expression of several oncoproteins. Further, HuR overexpression in 
cancer cells has been associated with poor-prognosis and therapy resistance. Therefore, we hypothesized that targeted 
inhibition of HuR in cancer cells should suppress several HuR-regulated oncoproteins resulting in an effective antican-
cer efficacy. To test our hypothesis, in the present study we investigated the efficacy of folate receptor-α (FRA)-targeted 
DOTAP:Cholesterol lipid nanoparticles carrying HuR siRNA (HuR-FNP) against human lung cancer cells.
Results: The therapeutic efficacy of HuR-FNP was tested in FRA overexpressing human H1299 lung cancer cell 
line and compared to normal lung fibroblast (CCD16) cells that had low to no FRA expression. Physico-chemical 
characterization studies showed HuR-FNP particle size was 303.3 nm in diameter and had a positive surface charge 
(+4.3 mV). Gel retardation and serum stability assays showed that the FNPs were efficiently protected siRNA from 
rapid degradation. FNP uptake was significantly higher in H1299 cells compared to CCD16 cells indicating a receptor-
dose effect. The results of competitive inhibition studies in H1299 cells demonstrated that HuR-FNPs were efficiently 
internalized via FRA-mediated endocytosis. Biologic studies demonstrated HuR-FNP but not C-FNP (control siRNA) 
induced G1 phase cell-cycle arrest and apoptosis in H1299 cells resulting in significant growth inhibition. Further, 
HuR-FNP exhibited significantly higher cytotoxicity against H1299 cells than it did against CCD16 cells. The reduction 
in H1299 cell viability was correlated with a marked decrease in HuR mRNA and protein expression. Further, reduced 
expression of HuR-regulated oncoproteins (cyclin D1, cyclin E, and Bcl-2) and increased p27 tumor suppressor protein 
were observed in HuR-FNP-treated H1299 cells but not in C-FNP-treated cells. Finally, cell migration was significantly 
inhibited in HuR-FNP-treated H1299 cells compared to C-FNP.
Conclusions: Our results demonstrate that HuR is a molecular target for lung cancer therapy and its suppression 
using HuR-FNP produced significant therapeutic efficacy in vitro.
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Background
Effective treatment of lung cancer continues to pose chal-
lenges resulting in a dismal overall five-year survival rate 
of less than 16  % [1]. Despite the availability of strong 
chemotherapy agents, therapeutic success is limited 
due to low tumor selectivity and increased non-specific 
cytotoxicity, the emergence of multi-drug resistance, 
and metastasis [2, 3]. Advances in molecular-targeted 
therapies have shown promise in clinical outcomes 
[4–6]. However, the emergence of secondary acquired 
mutations to the therapeutic has limited their continued 
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use for treating lung cancer [7, 8]. Therefore, new and 
improved therapies are needed to overcome the existing 
limitations of cancer therapy.
The human antigen R (HuR), an RNA binding protein, 
has been implicated in the regulation of mRNAs whose 
protein products have key roles in cancer cell prolifera-
tion, angiogenesis, and tumor-associated inflammation 
[9, 10]. HuR regulation of target mRNAs is based on the 
interaction between the three specific domains of the 
HuR protein and the AU-rich elements on the untrans-
lated region of the target mRNA [11]. Researchers have 
reported that HuR overexpression in various cancer types 
is associated with aggressive malignancy and is an indi-
cator of poor prognosis [9, 12–14]. We and others have 
observed elevated expression of HuR in human-derived 
non-small cell lung cancer (NSCLC) cells [14–16]. Since 
HuR is overexpressed in cancer cells and regulates sev-
eral oncoproteins, we hypothesized that small interfering 
RNA (siRNA)-mediated silencing of HuR will produce 
global knockdown of HuR-regulated oncoproteins result-
ing in reduced tumor cell survival.
Inhibition of HuR expression in cancer cells can be 
achieved with siRNA [15–18]. The high specificity and 
the expression-modulating capacity of siRNA make it a 
promising RNA interference (RNAi) tool for HuR inhibi-
tion. However, the vulnerability of siRNA therapeutics to 
degradation and rapid clearance in the in  vivo environ-
ment warrant a safe but efficient carrier for its delivery to 
the target [19, 20]. Nanoparticle (NP)-based gene delivery 
vehicles, which include a wide range of systems made up 
of polymers, silica, gold particles, and other hybrid sys-
tems, are gaining more attention due to their small size, 
ability to overcome biological barriers, and their specific 
gene delivery potency [20–22]. Liposomes or lipid-based 
NP systems also continue to be used for gene and drug 
delivery and continues to hold its wide use for therapeutic 
applications [5, 23, 24]. Studies from our laboratory and 
others have previously shown that DOTAP:Cholesterol 
(DOTAP:Chol) lipid-based NP can efficiently deliver 
therapeutic nucleic acid molecules to cancer cells both 
in  vitro and in  vivo [5, 23–26]. An added advantage of 
DOTAP:Chol. NP is its low toxicity and high transfection 
efficiency, which allowed its entry into clinical testing for 
lung cancer therapy [27]. Hence, we hypothesized that 
DOTAP:Chol. NP-mediated HuR siRNA delivery in lung 
cancer cells will result in specific and efficient knockdown 
of HuR producing a therapeutic response.
To test our hypothesis, we first developed a folate-con-
jugated DOTAP:Chol NP system (FNP) targeted towards 
folate receptor-α (FRA)-overexpressing lung cancer cells. 
Next, we tested the therapeutic efficacy of HuR siRNA 
containing FNP (HuR-FNP) in  vitro using human lung 
cancer (H1299) and normal lung fibroblast (CCD16) 
cells that varied in their FRA expression levels. We dem-
onstrate HuR-FNP treatment selectively targeted and 
inhibited tumor cell proliferation and cell migration with 
minimal cytotoxicity to normal cells. Molecular studies 
showed HuR-FNP-mediated silencing of HuR markedly 
reduced the expression of HuR-regulated oncoproteins in 
cancer cells but not in normal cells. Our work convinc-
ingly demonstrates that HuR is a molecular target for 
lung cancer therapy and its suppression using HuR-FNP 
produced significant therapeutic efficacy in vitro.
Results
Physico‑chemical characterization of FNP and HuR‑FNP
The scheme of step-by step synthesis of HuR-FNP is 
depicted in Fig.  1a. FNPs prepared by the thin-film 
hydration method when mixed with HuR siRNA readily 
formed HuR-NP complexes. The HuR-FNP complex akin 
to HuR-NP and NP showed a near-spherical structure, 
as revealed by transmission electron microscopy (TEM; 
Fig. 1b). Table 1 shows the particle size and zeta poten-
tial values in the step-by-step synthesis of HuR-FNP. 
Synthesized empty NP had an average size of 158.26 nm, 
which increased to 205.79 nm upon HuR siRNA loading. 
The particle sizes obtained were within the size range 
of previously reported DOTAP:Chol nanoparticles that 
employed similar preparation procedures [28, 29]. A 
further increase in size (303.3  nm) was observed when 
DSPE-PEG5000-Folate was post-inserted into HuR-NP. 
Zeta potential of NP also varied upon loading of siRNA, 
from +30.89 to −2.66  mV. This remarkable change in 
zeta potential from strong positive to slightly negative 
values might be attributed to the neutralization of cati-
onic charge by negatively charged siRNA. This finding 
also confirms siRNA binding to the nanoparticle. The 
addition of DSPE-PEG5000-Folate however reverted HuR-
FNP complex in having a net positive charge (+4.3 mV), 
though the charge was still near neutral.
FNP protects siRNA from degradation
The instability of siRNA in the physiological environment 
due to its susceptibility to serum-nuclease catalyzed degra-
dation, is a major limitation in RNA interference (RNAi)-
based gene therapy [20]. Therefore, we studied the siRNA 
protection efficiency of FNP and its ability to prevent 
siRNA degradation in the presence of serum prior to con-
ducting in  vitro biological studies. Gel retardation assay 
showed that, unlike the naked siRNA that was suscep-
tible to degradation when exposed to 50 % serum for 1 h, 
the siRNA contained within the FNPs was relatively intact 
and efficiently protected when incubated in the presence 
of 50 % FBS for 0.5 h to 1 h (Fig. 1c). This finding strongly 
suggests that the FNP is able to condense and protect the 
siRNA and delays the degradation by serum nucleases.
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Fig. 1 Synthesis and physico-chemical characterization of siRNA-FNP. a Scheme showing HuR-FNP preparation. b TEM image of NP, HuR-NP, and 
HuR-FNP. Scale bar denotes 100 nm. c Agarose gel electrophoretogram showing siRNA protection by FNP at different time (0, 0.5 and 1 h) points of 
incubation compared to naked siRNA exposed to serum for 1 h. Free siRNA not exposed to serum was used as internal marker. d siRNA release pro-
file over time from siRNA-FNP in PBS (pH 7.4) measured by Quanti-iT Picogreen Assay (top figure); and from fluorescently labeled siRNA (siGLO)-FNP 
in acetate buffer (pH 5.5) and in 50 % FBS containing PBS (pH 7.4) [bottom figure]
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siRNA release kinetics
To determine the release kinetics of siRNA from FNP, 
we conducted in vitro siRNA release profile study in PBS 
(pH 7.4), acetate buffer (pH 5.5) and 50 % FBS containing 
PBS (pH 7.4) (Fig.  1d). In general, the FNP system dis-
played a sustained siRNA release pattern (Fig. 1d, top and 
bottom figures). Around 15, 39 and 2.4 % of siRNA was 
released in the first hour in PBS, acetate buffer and 50 % 
FBS respectively. The initial high release rate over 1  h 
may be due to fast dissociation of loosely bound siRNA 
from FNP. Later at 24  h the release of siRNA reached 
66, 75, and 41  % in PBS, acetate buffer and 50  % FBS 
media respectively. This release pattern suggested that 
the siRNA will be released faster under acidic conditions 
such as that observed in the tumor microenvironment 
milieu albeit some degree of degradation is likely to occur 
when siRNA comes in contact with serum.
Evaluation of HuR and FRA expression levels in cell lines
Prior to studying the tumor-targeted delivery efficiency of 
HuR-FNP we determined the expression levels of FRA and 
HuR in H1299 and CCD16 cell lines that we have selected to 
use in the present study. The western blot analysis showed 
that the baseline HuR and FRA expression levels were high 
in H1299 cells compared to CCD16 cells (Fig. 2a). In fact, 
FRA expression in CCD16 cells was negligible.
Mole fraction of DSPE‑PEG5000‑Folate in the NP influences 
transfection efficiency
The effect of various DSPE-PEG5000-Folate mole frac-
tions (Mole frac. %) in the NP was evaluated for transfec-
tion efficiency in H1299 cells. NPs with varying mole % 
(0.005 to 0.1  %) of DSPE-PEG5000-Folate were formu-
lated with luciferase-expressing plasmid DNA. Figure 2b 
shows that luciferase activity increased with increased 
DSPE-PEG5000-Folate concentrations, until the highest 
activity was reached at 0.03 mol % in H1299 cells. Lucif-
erase activity expressed as relative light units (RLU)/μg 
of protein were 74,718 ±  28,129 and 192,234 ±  54,247 
at 24 and 48 h respectively after treatment with NP con-
taining 0.03  mol  % of DSPE-PEG5000-Folate. The FNP 
transfection efficiency, at its optimal ligand (folate) 
combination, was four fold higher than that of the cor-
responding unmodified NP (0  %). Further increases in 
DSPE-PEG5000-Folate mole fractions (0.05 and 0.1  %) 
reduced luciferase activity, indicating low cellular uptake 
of FNP. We found that the optimal transfection efficiency 
occurred at 0.03  mol  % of DSPE-PEG5000-Folate when 
inserted into HuR-NP. Also a further increase above 
0.03  mol  % of DSPE-PEG5000-Folate resulted in reduced 
transfection efficiencies in FRA expressing cells. The 
reduction in transfection is attributed to the increased 
PEG density at higher DSPE-PEG5000-Folate mole frac-
tions, which likely impedes the NP interaction with the 
cell membrane for successful DNA delivery to occur. Our 
result is consistent with a previous report suggesting the 
influence of PEG layer thickness in electrostatic interac-
tion between NP and cell membrane [36].
Cell uptake of FNP corresponds to FRA expression levels
To investigate the cell uptake efficiency of FNP, H1299 
and CCD16 cells were transfected with FNP containing 
fluorescent siRNA (siGLO) and compared to NP contain-
ing siGLO (NP = no Folate ligand). The uptake of siGLO 
containing FNP and NP by the cells was determined over 
time and expressed as percent uptake of siGLO-FNP 
over siGLO-NP. A time-dependent increase in fluores-
cence was observed in siGLO-FNP-treated H1299 cells 
compared to CCD16 cells (p  <  0.05; Fig.  3a) indicating 
enhanced siGLO-FNP uptake by tumor cells than normal 
Table 1 Particle size and  zeta potential of  siRNA contain-
ing NPs
Components Diameter (nm) Zeta potential (mV)
NP 158.26 30.89
HuR-NP 205.79 −2.66
HuR-FNP (0.03 mol %) 303.3 4.3
Fig. 2 a Western blot showing HuR and Folate receptor-α (FRA) 
expression levels in H1299, and CCD16 cells. b Optimization of DSPE-
PEG5000-Folate mole fraction (%) in NP was achieved by determining 
the luciferase activity in H1299 cells that were transfected with NP 
modified with varying mole fractions (%) of DSPE-PEG5000-Folate and 
carrying a luciferase-expressing plasmid. Untreated cells served as 
control. Error bars denote SD
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cells. This observation was further supported by the live 
cell fluorescence images obtained using the Operetta 
imaging system (Fig.  3b). Enhanced siGLO fluorescence 
was observed in H1299 cells than in CCD16 cells both at 
4 and 24 h after transfection. These results demonstrate 
selective uptake and delivery of siGLO-FNP occurred in 
FRA overexpressing H1299 cells than in low to no FRA 
expressing CCD16 cells.
Enhanced uptake of FNP in H1299 cells occurs via folate 
receptor‑mediated endocytosis
Studies have previously shown that folate-conjugated 
NPs enter the cells via receptor-mediated endocytosis 
[30–32]. We therefore studied the cellular internaliza-
tion mechanism of FNP in folate receptor-positive H1299 
cells. FNPs carrying fluorescent siRNA (siGLO-FNP) 
were added to H1299 cells and the uptake of siGLO-FNP 
was determined by incubating the cells at two different 
incubation temperatures (+4 and +37 °C), because tem-
perature influences the rate of receptor-mediated endo-
cytosis [33]. Figure  4a shows the fluorescence intensity 
values of siGLO expression in H1299 cells incubated 
with siGLO-FNP at +37 and +4 °C relative to untreated 
control cells. At 1  h, the fluorescence intensity of cells 
incubated at +37 °C was significantly higher than that of 
cells incubated at +4  °C (p < 0.05), indicating enhanced 
siGLO-FNP uptake. The fluorescence intensity at later 
time points increased from twofold to sixfold in cells 
incubated at +37  °C, compared with cells incubated at 
+4  °C (p  <  0.01). This indicates a high rate of siGLO-
FNP uptake via active receptor-mediated endocytosis 
at +37  °C. In contrast, the low siGLO-FNP expression 
observed over time at +4  °C is due to energy depletion 
and reduced endocytic activity. This result suggests the 
involvement of folate receptor-mediated endocytosis of 
FNP in H1299 cells.
To further test the specificity of FNP towards FRA, we 
carried out FNP uptake studies in three groups of H1299 
cells: (1) cells incubated in regular RPMI1640 medium 
containing trace amounts of folic acids (indicated as 
RPMI1640), (2) cells incubated in RPMI1640 medium 
containing an excess of exogenous folic acid (+1  mM), 
and (3) cells incubated in RPMI1640 medium free of 
folic acid (–folic acid). FNP uptake by H1299 cells in folic 
acid-free medium was significantly enhanced (measured 
as fluorescence intensity of siGLO) at 4–24 h, compared 
with FNP uptake by cells in regular medium containing 
trace amounts of folic acid (Fig. 4b; p < 0.05). This result 
indicates the presence of free folic acid in the culture 
medium likely competes with FNP for FRA thereby affect-
ing FNP uptake by the cells. To further test the speci-
ficity and the possibility of free folic acid competing for 
FRA, H1299 cells were treated with FNP in the presence 
of exogenous folic acid (1  mM). A marked reduction in 
FNP uptake and relative fluorescence intensity in H1299 
cells was observed at all time points tested when excess of 
exogenous folic acid was present in the culture medium 
compared with cells in culture medium containing trace 
amounts of folic acid (Fig. 4c; p < 0.05). Our results dem-
onstrate that the FNP specifically interacts with FRA to 
facilitate cell uptake and the predominant mechanism of 
FNP uptake occurred via receptor-mediated endocytosis.
HuR‑FNP‑induced cell growth inhibition correlated 
with FRA expression
siRNA-mediated HuR knockdown has been reported to 
induce cell apoptosis [34, 35] To assess the consistency of 
this observation in our studies and to evaluate whether 
the differential uptake of HuR-FNP complemented its 
cytotoxic potential in H1299, and CCD16 cells, we per-
formed cell growth inhibition studies. Figure 5 shows the 
cell growth inhibition induced by C-FNP and HuR-FNP 
over the no-treatment controls. The cell growth inhibi-
tion induced by C-FNP and HuR-FNP in H1299 cells was 
1.3 and 17.3  % respectively at 24  h and 3.4 and 29.1  % 
respectively at 48 h. These results demonstrate that HuR-
FNP-induced inhibition was significantly larger than the 
inhibition observed in C-FNP-treated H1299 cells at the 
Fig. 3 a SiGLO-FNP uptake over siGLO-NP over time in H1299 was 
significantly increased over time compared to uptake in CCD16 
cells. b Fluorescent images of siGLO-FNP cell uptake in H1299, and 
CCD16 cells at 4 and 24 h post FNP treatment. (error bars denote SD; 
*p < 0.05; **p < 0.01)
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two time-points tested (p < 0.05). In the normal CCD16 
cells, C-FNP and HuR-FNP treatment produced 3.6 and 
10.8 % growth inhibition at 24 h and 6.7 and 10.5 % inhi-
bition at 48 h (p < 0.05). Although growth inhibition was 
observed in HuR-FNP-treated CCD16 cells and may 
raise some concern, there was approximately a three-
folds difference in inhibition between HuR-FNP-treated 
-H1299 and -CCD16 cells at 48 h indicating tumor-cell 
selectivity. Further, the difference in inhibition between 
C-FNP and HuR-FNP-treated CCD16 cells was only 
3.9 % when compared to a difference of 25.7 % between 
the two treatment groups in H1299 cells at 48 h. These 
results demonstrate HuR-FNP efficiently and selectively 
inhibited tumor cell proliferation and the difference 
in the inhibitory activity observed between H1299 and 
CCD16 cells is attributed to differences to different lev-
els of FRA expression.
Fig. 4 Mechanism and specificity of FNP uptake in FRA-expressing H1299 cells. a FNP uptake by H1299 cells, measured by fluorescence intensity 
of siGLO, was markedly reduced at +4 °C compared to +37 °C. b FNP uptake measured by fluorescence intensity of siGLO was greatly increased in 
the absence of folic acid in the culture medium at all time-points tested compared to FNP uptake in the medium containing trace amount of folic 
acid. c Addition of excess of exogenous folic acid (1 mM) to the culture medium reduced the FNP uptake compared to FNP uptake in the medium 
containing trace amount of folic acid. (error bars denote SD; *p < 0.05; **p < 0.01)
Fig. 5 Cell growth inhibition in H1299, and CCD16 cells at 24 and 
48 h after exposure to C-FNP or HuR-FNP treatment was compared 
with no-treatment control. (error bars denote SD; *p < 0.05)
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FRA modulates HuR‑FNP‑mediated tumor growth 
inhibition
Since HuR-FNP treatment produced significant growth 
inhibition in H1299 cells compared to CCD16 cells, we 
next determined if the inhibitory activity was modulated 
by FRA expression and FRA-mediated HuR-FNP uptake 
by the cells. HuR-FNP-mediated growth inhibitory activ-
ity was markedly reduced in the presence of excess of 
exogenous folic acid (1  mM; 14.8  % inhibition) in the 
culture medium when compared to the growth inhibi-
tion in the absence of excess of folic acid (25.4 %; p < 0.05; 
Fig. 6a) in the medium. Correlating with the diminished 
HuR-FNP-mediated inhibitory activity in cell growth was 
the reduced inhibition of HuR mRNA and protein expres-
sion when excess folic acid was present in the medium 
(Fig. 6 b, c; p < 0.01). In sharp contrast, lack of folic acid 
in the culture medium resulted in enhanced HuR-FNP-
mediated growth inhibitory activity and increased sup-
pression of HuR protein expression in H1299 cells when 
compared to the HuR-FNP-treated cells grown in regu-
lar culture medium that contained trace amounts of folic 
acid (data not shown).
Next we determined the effect of HuR-FNP on nor-
mal CCD16 cells similar to the studies described above 
for H1299. HuR-FNP produced minimal cytotoxicity in 
CCD16 cells that was further reduced in the presence of 
excess of folic acid and correlated with HuR mRNA and 
protein expression (Fig.  6d–f). The observed results are 
consistent with our FNP uptake data (Figs. 3, 4) and dem-
onstrate that HuR-FNP-mediated inhibitory activity spe-
cifically occurs via FRA and can be regulated by FRA as 
evidenced by the greater cytotoxicity in H1299 cells com-
pared to CCD16 cells.
HuR‑FNP treatment suppresses HuR and HuR‑regulated 
proteins and induces apoptosis in cancer cells
We next investigated the expression levels of HuR and 
HuR-regulated proteins (cyclin D1, cyclin E, Bcl2 and 
p27) in HuR-treated H1299 (Fig. 7a) and CCD16 (Fig. 7b) 
cell lines. In H1299 cells, HuR-FNP treatment markedly 
suppressed HuR that was accompanied with a concomi-
tant decrease in cyclin D1, cyclin E and Bcl2 expres-
sion (Fig.  7a) at the two time-points tested compared 
to expression of these proteins in C-FNP treatment and 
untreated control. Expression of p27, unlike the other 
proteins analyzed, however was greatly increased in HuR-
FNP treated cells compared to the two control groups at 
both 24 and 48 h (Fig. 7a). In CCD16 cells, HuR inhibi-
tion was negligible in HuR-FNP treated cells compared to 
C-FNP treated and untreated control cells at both 24 and 
48 h. Further, no significant change in the expression of 
cyclin-D1 and -E, Bcl2, and p27 proteins was observed in 
HuR-FNP treatment compared to C-FNP treatment and 
untreated control (Fig. 7b). In fact, slight increase in the 
expression of these proteins was observed in HuR-FNP 
treated cells when compared to the two control groups.
Next we investigated whether silencing of HuR results 
in tumor cell apoptosis as previous studies have reported 
HuR knockdown induced cell apoptosis [34, 35]. As 
shown in Fig. 7c, a marked induction of apoptosis as evi-
denced by cleavage of caspase 9 and PARP was observed 
in HuR-FNP-treated H1299 cells compared to C-FNP-
treated and untreated control cells. Together, our results 
demonstrate that HuR-FNP is capable of delivering HuR 
siRNA selectively to FRA expressing tumor cells and pro-
ducing cell-specific knockdown of HuR and HuR-regu-
lated target proteins resulting in tumor cell apoptosis.
HuR‑FNP induces G1 phase cell cycle arrest in lung cancer 
cells
In the present study HuR-FNP treatment reduced both 
cyclin-D1 and -E and increased p27 protein expression 
in H1299 cells. We therefore investigated if there were 
any changes in the cell-cycle phases, especially in the 
G1 phase, after HuR-FNP treatment. Cell cycle analysis 
showed HuR-FNP treatment produced a G1 phase cell 
cycle arrest in H1299 cells as evidenced by the marked 
increase in the number of cells in the G1 phase when 
compared to C-FNP treatment (Fig. 8; p < 0.05). The per-
cent increase in the G1 phase in HuR-FNP-treated cells 
over C-FNP-treated cells was 15 and 12 % at 24 and 48 h. 
In CCD16 cells, the G1 phase was observed to decrease 
in HuR-FNP-treated cells compared to C-FNP-treated 
cells (Fig.  8; p  <  0.05). Our results demonstrate that 
silencing of HuR via HuR-FNP modulates p27 and cyc-
lin-D and -E expression resulting in G1 phase cell-cycle 
arrest in tumor cells but not in normal cells.
HuR‑FNP inhibits tumor cell migration
Cancer cell migration is a critical event in metastasis. 
Studies by us and other have previously shown that HuR 
regulates the expression of several oncoproteins such as 
actin, matrix metalloprotease (MMP)-9, urokinase-type 
plasminogen activator (uPA) and its receptor (uPAR), 
all of which are known to play an important role in can-
cer cell migration and invasion resulting in metastasis 
[16, 36, 37]. Therefore, silencing of HuR should suppress 
the expression of these and additional proteins and pro-
ducing a net inhibitory activity on cell migration and 
invasion.
We therefore investigated whether HuR-FNP-mediated 
HuR gene silencing in H1299 cells inhibit cell migration. 
Cells treated with C-FNP and HuR-FNP was compared 
with untreated control cells for their migratory activity 
at 24 and 48 h. A significant inhibition of cell migration 
was observed in HuR-FNP-treated cells when compared 
Page 8 of 17Muralidharan et al. J Nanobiotechnol  (2016) 14:47 
Fig. 6 FRA modulates HuR-FNP efficacy. a HuR-FNP-mediated growth inhibition of H1299 cells was diminished in the presence of excess of folic 
acid (1 mM) in the culture medium compared to HuR-FNP inhibition in the absence of excess folic acid. HuR-FNP-mediated inhibitory activity on 
the expression of b HuR protein and c mRNA expression levels were also abrogated the presence of excess of folic acid (1 mM) compared to HuR-
FNP treatment in the absence of excess folic acid in H1299 cells. d HuR-FNP-mediated growth inhibition was less in CCD16 cells that was further 
diminished in the presence of excess of folic acid (1 mM). e HuR protein and f mRNA expression levels were not markedly affected in CCD16 cells in 
the presence of excess folic acid compared to in the absence of excess folic acid. (error bars denote SD; *p < 0.05; **p < 0.01)
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Fig. 7 Expression of HuR, and HuR-regulated proteins in cells treated with C-FNP or HuR-FNP. Untreated cells served a control. a H1299, and b 
CCD16. Bar graphs represent semi-quantitative analysis of the protein expression detected by western blotting. Beta-actin was used as internal load-
ing control. c HuR-FNP-treated H1299 cells underwent apoptosis as indicated by cleavage of caspase-9 and PARP at both 24 and 48 h after treatment 
compared to C-FNP-treated and untreated control cells. (*p < 0.05; **p < 0.01; NS not significant)
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to C-FNP-treatment and untreated control cells at both 
24 and 48  h (p  <  0.001; Fig.  9). The HuR-FNP-treat-
ment reduced cell migration by 62 and 75  % at 24 and 
48  h respectively when compared to untreated control. 
Although, inhibitory activity on cell migration was also 
observed in C-FNP treatment (12 and 14  % inhibition) 
compared to untreated control cells (p < 0.05), they were 
markedly less than that observed in HuR-FNP treatment 
(62 and 75  % inhibition). These results clearly demon-
strate that silencing of HuR by HuR-FNP inhibited tumor 
cell migration.
Discussion
In the present study we studied the efficacy of silenc-
ing HuR in lung cancer cells using FNP that is directed 
towards FRA overexpressing cancer cells. The rationale 
Fig. 8 HuR-FNP induces G1 phase cell-cycle arrest and inhibits cell migration in lung cancer cells. Cell cycle analysis showed HuR-FNP induced G1 
cell-cycle arrest in H1299 cells but not in CCD16 cells at both 24 and 48 h after treatment. (*p < 0.05)
Fig. 9 HuR-FNP treated tumor cells exhibit reduced cell migration. Cell migration studies showed that both C-FNP and HuR-FNP inhibited cell 
migration when compared to untreated control. However, the inhibition on cell migration exerted by HuR-FNP was greater than C-FNP at the two 
time-points tested. (*p < 0.05; **p < 0.01)
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to use FNP was to reduce non-specific toxicity to normal 
cells and increase the therapeutic efficacy against tumor 
cells as majority of cancer therapies that are currently 
available are limited by cytotoxicity to normal tissues. 
Further, our objective to target HuR is based on prior 
reports from our laboratory and others demonstrating 
the therapeutic potential of RNAi mediated knockdown 
in broad-spectrum of human cancer cells [16, 38–42].
Physico-chemical characterization of the FNPs showed 
favorable characteristics in terms of size, shape, and 
charge qualifying them as a potential therapeutic nano-
carrier. Further, the NPs exhibited proficient protection 
of the siRNA and is of prime importance as it is well 
known that siRNA is unstable in the physiological envi-
ronment and are susceptible to serum-nuclease catalyzed 
degradation and thus poses a limitation in RNA interfer-
ence (RNAi)-based cancer gene therapy [20]. The siRNA 
protection observed in the present study is likely due to 
the strong charge interaction between the cationic NP 
and anionic siRNA resulting in compaction of siRNA 
into the core of NP and thus protecting from unfavorable 
physiological components, such as the serum nucleases.
Another favorable characteristic of our FNP system 
was the slow and controlled release of the siRNA in phys-
iological pH, after a high release rate observed in the ini-
tial hour of study. Slow and controlled release of siRNA is 
advantageous as it is likely to produce a prolonged inhibi-
tory activity thereby reducing the frequency of treat-
ment. The initial burst release observed at 1 h may be due 
to fast dissociation of loosely bound siRNA from FNP 
followed by slow release that could be attributed to the 
presence of PEG chains and folate on the NP that retards 
the rapid dissociation of the remained of the siRNA in 
the NP into the releasing media.
Biological and functional studies showed that FNP 
was selective and specific towards FRA expressing lung 
cancer cells but not towards low-no FRA expressing nor-
mal cells and that FNP uptake by the cells was receptor-
mediated. Earlier studies showed that folate-conjugated 
NPs enter the cells via receptor-mediated endocytosis 
[30, 43, 44]. In this context, it was important to under-
stand the mechanism of cellular internalization of FNP in 
FRA-positive H1299 cells. The rate of siGLO-FNP uptake 
was influenced by the incubation temperature of cells 
undergoing treatment. A low cellular uptake at +4  °C 
and a higher uptake at +37  °C of siGLO-FNP was sug-
gestive of the involvement of receptor-mediated endocy-
tosis, because temperature affects the energy dependent 
receptor-mediated endocytosis mechanism [30]. Simi-
larly we have also proved the target specificity of FNP 
towards FRA overexpressing tumor cells by competitive 
inhibition study in the presence, absence and exogenous 
folic acid in the incubation media. The poor FNP uptake 
observed in the presence of exogenous free folic acid is 
attributed to competitive binding and blocking of most 
of the available FRA by folic acid. Altogether, our results 
demonstrate that the FNP specifically interacts with FRA 
to facilitate cell uptake and the predominant mecha-
nism of FNP uptake occurred via receptor-mediated 
endocytosis.
To assess the consistency of this observation in our 
studies and to evaluate whether the differential uptake 
of HuR-FNP complemented its cytotoxic potential in 
H1299, and CCD16 cells, we performed cell growth inhi-
bition studies. SiRNA-mediated HuR knockdown has 
been reported to induce cell apoptosis [32, 34]. Hence by 
knocking down HuR by HuR-FNP treatment we observed 
a remarkable difference in cell growth inhibition between 
H1299 and CCD16 cells. This result suggested that HuR-
FNP efficiently and selectively inhibit tumor cell pro-
liferation and the difference in the inhibitory activity 
observed between H1299 and CCD16 cells is attributed 
to different levels of FRA expression. Similar observa-
tion was recently reported in ovarian cancer cells where 
HuRsiRNA was suppressed using folate receptor targeted 
3DNA nanocarriers both in vitro and in vivo [41].
Since HuR-FNP treatment produced growth inhibition 
in H1299 cells and not in CCD16 cells, we next investi-
gated the expression levels of HuR and HuR-regulated 
proteins (cyclin D1, cyclin E, Bcl2 and p27) in the two cell 
lines and its effects on cell-cycle. The rationale to analyze 
for these proteins is based on previous reports demon-
strating the presence of AU rich-elements (ARE) in the 
3′ and/or 5′ untranslated regions (UTR) of the corre-
sponding mRNAs and binding of HuR to the UTR results 
in mRNA regulation leading to suppression (cyclin-D1 
and -E, Bcl2) or repression (p27) of these proteins [16, 
34, 45, 46]. It is well known that cell cycle progression is 
regulated by cyclins and the associated cyclin-dependent 
kinases (cdks) [47, 48]. Cyclin D1 is an important acti-
vator of Cdk4 and Cdk6, which regulate cell cycle pro-
gression through the G1 phase [47]. Similarly, cyclin 
E is critical for cell cycle progression through the G1/S 
transition [49]. Another cell-cycle regulator known to 
be modulated by HuR is P27. P27 is a cyclin-dependent 
kinase (CDK) inhibitor that regulates cell-cycle by induc-
ing cell-cycle arrest in the G1 phase [35, 46]. Further, loss 
of p27 expression in human cancer cells has been shown 
to promote cell proliferation indicating p27 also oper-
ates as a tumor suppressor [50, 51]. Studies have shown 
the presence of 5′ untranslated region (UTR) sequence 
in the p27 promoter to which HuR binds and suppress 
p27 protein expression [46]. However, upon inhibit-
ing HuR, the suppressive activity of HuR is lost result-
ing in repression of p27 protein expression. Treatment 
with HuR-FNP reduced HuR protein levels in the tumor 
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cells with concomitant reduction in cyclin-D1 and -E 
and increased P27 protein expression, an observation 
that concurred with previous reports [16, 46]. Further, 
changes in expression of these proteins correlated with 
the induction of cell cycle arrest in the G1 phase in HuR-
FNP-treated tumor cells. In the normal cells no signifi-
cant change in HuR or HuR-regulated proteins and cell 
cycle phase was observed. This observation concurs with 
previous reports demonstrating HuR inhibition in cancer 
cells produces G0/G1 phase arrest [16, 32, 45].
The ability of HuR-FNP to reduce Bcl2, an anti-apop-
totic protein that has been shown to play a key role in cell 
survival and contribute to resistance against cytotoxics 
[34, 50], provides new opportunity for testing HuR-FNP 
efficacy in Bcl-2 overexpressing drug-resistant cancer 
cells. Further, combinatorial siRNA therapies against 
HuR and Bcl2 can be envisioned that should produce an 
enhanced anticancer activity. While these concepts are 
of interest and of relevance to cancer treatment, they are 
beyond the scope of the present study.
Finally, we have shown HuR suppression by HuR-FNP 
inhibited tumor cell migration, a phenomenon that was 
consistent with previous reports [16, 52, 53]. The mech-
anism by which HuR regulates tumor cell migration and 
invasion is documented to involve several oncoproteins 
such as actin, matrix metalloprotease (MMP)-9, uroki-
nase-type plasminogen activator (uPA) and its receptor 
(uPAR), and the CXCR-4 chemokine receptor all of which 
are known to play an important role in cancer cell migra-
tion and invasion resulting in metastasis [16, 53, 54].
Together, our results convincingly demonstrate that 
HuR-FNP is capable of delivering HuR siRNA selectively 
to FRA expressing tumor cells and producing cell-spe-
cific knockdown of HuR and HuR-regulated target pro-
teins producing minimal cytotoxicity to normal cells. 
Our exciting in vitro study results provide an impetus for 
testing HuR-FNP in vivo as monotherapy and as combi-
natorial therapy using conventional chemotherapeutics 
and molecularly targeted therapeutics for lung cancer.
Conclusion
In the present study we have developed and tested the fea-
sibility of a tumor-targeted nanoparticle siRNA delivery 
system for selectively targeting tumor cells and silence HuR, 
and establish HuR as a molecular target for lung cancer 
therapy. We demonstrated HuR-FNP is preferentially taken 
up by FRA overexpressing lung cancer cells and produce 
tumor cell cytotoxicity by inhibiting HuR with minimal 
cytotoxicity to normal cells. The antitumor activity of HuR-
FNP is produced by a combination of cell growth inhibition, 
cell cycle arrest, suppression of oncoproteins, and impeded 
cell migration. While our study results are exciting, it is to 
be noted that additional preclinical studies are warranted 
prior to clinical testing. Our study results also provide an 
avenue for conducting combinatorial therapy studies against 
drug-resistant cancer cells. Finally, HuR-FNP-based can-
cer therapy can be applied in treating a broad-spectrum of 




(DOTAP), cholesterol, and 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[folate(polyethylene gly-
col)-5000] (DSPE-PEG5000-Folate) were purchased from 
Avanti Polar Lipids (Alabaster, AL, USA). Folic acid was 
purchased from Sigma-Aldrich Chemicals (St. Louis, 
MO, USA). RPMI-1640 medium, Hams-F12 medium, 
folic acid-free RPMI medium, and fetal bovine serum 
(FBS) was purchased from GIBCO BRL Life Technolo-
gies (New York, NY, USA). Luciferase assay reagent and 
lysis buffers were obtained from Promega (Madison, WI). 
Control siRNA (5′ UAA GGC UAU GAA GAG AUA C 
3′), and HuR-siRNA (5′ UCA AAG ACG CCA ACU UGU 
A 3′) were purchased from Dharmacon (Lafayatte, CO). 
Luciferase (luc) expression plasmid vector was obtained 
from Clonetech (Mountain View, CA, USA).
Cell lines
Human non-small-cell lung carcinoma (NSCLC) cell 
line (H1299) and human normal lung fibroblast cell line 
(CCD16) were obtained from American Type Culture 
Collection (ATCC, Rockville, MD, USA). Cells were 
maintained in appropriate culture medium as previ-
ously described [16]. The cell lines were authenticated to 
be of human origin by single tandem repeat assay (STR; 
IDEXX Bioresearch, Columbia, MO, USA).
Synthesis of cationic lipid nanoparticles
Cationic lipid nanoparticles (NPs) were synthesized using 
the thin-film hydration method as previously described 
[55]. Briefly, a 20 mM equivalent of DOTAP and Chol was 
mixed and dissolved in chloroform. A thin DOTAP:Chol 
film was created in a round-bottom flask with the help 
of a Rotavapor® under ambient conditions, and was vac-
uum-dried. Dextrose (5  %) in sterile water (D5W) was 
used as hydration solution to create liposomes from the 
dried lipid film. The liposomes were then sequentially 
extruded through an Avanti® Mini-Extruder (filters with 
1–0.1 μM pores) to produce liposomes with reduced par-
ticle size and low polydispersity. For preparation of DNA- 
or siRNA-containing NPs, diluted DOTAP:Chol stock 
solution and DNA or siRNA solution in D5 W was mixed 
in equal volumes to give a final concentration of 4  mM 
DOTAP:Chol containing 1  µg DNA or 100  nM siRNA 
equivalent per well of a six-well plate.
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Preparation of folate‑conjugated NP
DSPE-PEG5000-Folate was inserted into preformed DNA- 
or siRNA-containing NPs using the post-insertion tech-
nique [16]. The post-insertion mechanism involves the 
insertion of acyl chains of DSPE phospholipid into the 
DOTAP:Chol lipid bilayer as a result of hydrophobic–
hydrophobic interaction and has shown to be a successful 
method of lipid NP modification [43]. While addition of 
PEG chains (via DSPE-PEG) has successfully been shown 
to impart long circulating properties to NP [44], folate 
contributes to their targeting ability.
Briefly, a stock solution of DSPE-PEG5000-Folate 
(17  µM) was prepared by thin film hydration. In the 
next step, various concentrations of DSPE-PEG5000-
Folate (0.005, 0.01, 0.03, 0.05, or 0.1  mol fraction  % of 
DOTAP:Chol) were mixed with DNA- or siRNA-con-
taining NP by vigorous pipetting. Pipetting was followed 
by incubation at room temperature (RT) for 60  min to 
form FNPs. The FNPs were then dialyzed against distilled 
water overnight at 4  °C. After dialysis, the FNP suspen-
sion was stored in sterile 1-ml screw-cap tubes at 4  °C. 
The tubes were labelled as HuR-FNP and C-FNP for FNP 
carrying HuR siRNA and control siRNA, respectively. 
Unmodified NPs were synthesized without the addition 
of DSPE-PEG5000-Folate.
Nanoparticle characterization
Size, shape, and zeta potential
Particle size distribution and zeta potential of the NP formu-
lations were determined using the Brookhaven ZetaPALS 
instrument. The shape and size of the NPs stained by uranyl 
acetate (2 % for 5 min) were analyzed using a Hitachi H-7600 
transmission electron microscope (TEM) at the Oklahoma 
Medical Research Foundation (OMRF) core facility.
siRNA protection assay
An electrophoretic mobility assay of siRNA-loaded NP 
formulations was conducted to determine whether FNP 
formulations protect siRNA in the presence of serum 
[16]. Briefly, siRNA-containing FNPs were incubated 
with 50  % FBS at 37  °C for 0, 30, and 60  min, respec-
tively. Then, an aliquot of each sample was collected and 
was subjected to gel electrophoresis in 1.2 % agarose gel 
at 100  V for 30  min in Tris-acetate-EDTA buffer (TAE; 
pH 8.0). The efficiency of siRNA protection by FNP was 
assessed by examining the gel for retardation of encap-
sulated siRNA in the wells, and comparing this with 
migrating free siRNA control. The gel was stained with 
ethidium bromide (Sigma Chemicals). Images were cap-
tured using a gel documentation system (Syngene, Fred-
erick, MD, USA).
siRNA release profile
100 μl of siRNA (100 nM) loaded FNP was suspended in 
phosphate-buffered saline (PBS; pH 7.4) and incubated at 
37 °C with gentle shaking at 120 rpm. At predetermined 
time points, the FNP suspension in PBS was centrifuged 
for 10 min at 12,000g. The supernatant was removed and 
the pellet was resuspended in fresh PBS. The collected 
supernatant was reacted with Quant-iT Picogreen rea-
gent® (Thermo Fisher Scientific, USA) per the manu-
facturers’ protocol. The reaction product was subjected 
to fluorescence measurement at 485  nm excitation and 
535 nm emission wavelengths using an EnVision® multi-
label reader (Perkin Elmer, Santa Clara, CA, USA). The 
amount of siRNA in the releasing media was quantified 
and represented as the percentage of siRNA encapsulated 
in FNP.
Further, to show the release profile of siRNA in low pH 
conditions and also in physiological pH in the presence 
of serum, we carried out separate in vitro release experi-
ments using fluorescently labelled siRNA (siGLO) loaded 
FNP. Briefly, siGLO-FNP (200  μl) samples were sus-
pended in acetate buffer (pH 5.5) and 50 % fetal bovine 
serum (FBS) containing PBS (pH 7.4) in separate vials 
and incubated at 37  °C with gentle shaking at 120  rpm. 
At predetermined time intervals the siGLO-FNP samples 
were centrifuged (12000×g; 15 min) and the supernatants 
were withdrawn and replaced with respective (fresh) 
buffers. The supernatants were analyzed using Envi-
sion Multilabel reader at 557 nm excitation and 570 nm 
emission wavelengths for siGLO. The amount of siRNA 
release was quantified and represented as percentage of 
siRNA released from FNP.
Folate optimization
To choose the NP formulation with the optimal target-
ing and transfection efficiency, luciferase plasmid DNA 
carrying NPs decorated with various DSPE-PEG5000-
Folate mol fractions (0.005, 0.01, 0.03, 0.05 %, or 0.1 mol 
fraction  %) were prepared and tested in  vitro. Briefly, 
H1299 cells (1 × 105 cells/well) were seeded in six-well 
plates and were transfected with FNPs carrying lucif-
erase reporter plasmid DNA (1  μg/well) in serum-free 
medium. After 6  h of transfection, the medium was 
replaced with RPMI-1640 containing 2 % FBS and incu-
bation was continued at 37 °C, 5 % CO2. The cells were 
harvested at 24 and 48  h after transfection. Luciferase 
expression was determined using a luciferase assay kit 
(Promega, Madison, WI, USA) as previously described 
[16, 37]. Cells grown without treatment and cells treated 
with DSPE-PEG5000-Folate-free (unmodified or 0  % 
folate) NPs served as controls.
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Cellular uptake of FNP
Lung cancer (H1299) and normal lung fibroblast 
(CCD16) cells that have differential expression of folate 
receptor were chosen for studying the cellular uptake 
of FNP. Briefly, 1  ×  105 cells/well was seeded in six-
well plates. The cells were transfected with either NP or 
FNP that were loaded with fluorescently labelled siRNA 
(siGLO, Dharmacon; 100  nM equivalent) in serum-free 
medium. The cells were harvested at various time (1, 4, 
6, and 24 h) points after transfection. The cellular uptake 
of FNP was determined quantitatively using an Envision 
multilabel plate reader and qualitatively using the Oper-
etta imaging system (Perkin Elmer).
To determine whether the uptake of FNP is facili-
tated by receptor-mediated endocytosis, H1299 cells 
(1 × 105 cells/well) were transfected with FNP containing 
fluorescently labelled siRNA (siGLO, 100 nM) and incu-
bated for various time (1, 4, and 6 h) points at either 37 or 
4 °C. After the incubation period, the cells were washed 
with PBS, were harvested, and were analyzed with an 
Envision multiple plate reader.
To determine the role of folate receptor in FNP inter-
nalization, cell uptake studies were conducted in the 
presence and absence of free folic acid in culture medium 
and with or without 1  mM exogenous folic acid. The 
experimental setup used H1299 cells (1 × 105 cells/well) 
grown for 24  h in RPMI medium, with or without folic 
acid. The next day, cells were transfected with FNP con-
taining fluorescently labelled siRNA (siGLO, 100 nM). At 
various time (1, 4, 6, and 24 h) points after transfection, 
the cells were harvested and were analyzed quantitatively 
using an Envision multilabel plate reader.
Cell viability assay
The efficiency of HuR-FNP in lung cancer cell growth 
inhibition was determined using the standard Trypan 
blue exclusion assay method as previously described [16, 
55, 56]. Briefly, cells (H1299, CCD16; 1 × 105 cells/well) 
seeded in six-well plates were treated with FNP con-
taining control siRNA (C-FNP) or HuR-FNP (100  nM 
siRNA) in serum-free medium. After 6  h of incubation, 
the medium was replaced with 10  % FBS-containing 
medium. Cells that did not receive any treatment served 
as control. At 24 and 48 h after treatment, the cells were 
harvested and the number of viable cells was counted. 
The results were expressed as percentage inhibition over 
untreated control cells. The experiments were repeated 
three times for reproducibility and were analyzed 
statistically.
Quantitative (Q) RT‑PCR assay
Total RNA from FNP treated cells was isolated using Tri-
zol reagent (Life Technologies, Grand Island, NY, USA) 
and the RNA quality was determined using Denovix 
DS11 spectrophotometer as previously described [37]. 
Complimentary DNA (cDNA) was synthesized from 
RNA (2 µg/sample) using a Quant script cDNA synthesis 
kit (Bio-Rad, Richmond, CA, USA). Then, 3 µl of cDNA 
was amplified by real-time (RT)-PCR (Bio-Rad CFX96™ 
TouchReal-Time PCR Detection System) using the premix 
iQ SYBR green QRT-PCR kit (Bio-Rad) and human HuR-
specific oligonucleotide primers (Forward- 5′ ATGAA 
GACCACATGGCCGAAGACT 3′- Sense; Reverse-5′ 
TGTGGTCATGAGTCCTTCCACGAT 3′-Antisense). 
Thermal cycling was programmed as follows: 50  °C for 
2  min, 95  °C for 3  min, then 40 cycles of 95  °C for 10  s 
alternating with 60 °C for 10 s and 72 °C for 30 s. The cycle 
threshold (Ct) value assessed by RT-PCR was noted for 
the transcripts and was normalized with human GAPDH 
(Forward-5′AGCCTCAAGATCATCAGCAATGCC 
3′ and Reverse- 5′ TGTGGTCATGAGTCCTTCCAC 
GAT 3′). The changes in mRNA expression levels were 
expressed as fold change relative to control  ±  standard 
deviation (SD). Each sample was run in triplicate. The 
experiments were repeated at least twice for reproducibil-
ity and statistical calculation.
Cell cycle analysis
Cells (H1299, CCD16) were transfected using C-FNP and 
HuR-FNP (100 nM siRNA) as described in the cell viabil-
ity assay above. At 24, and 48 h after treatment, the cells 
were collected, processed and were subjected to flow 
cytometric analysis as previously described [26, 37].
Western blotting
Total protein extracted from cells that underwent vari-
ous treatments was subjected to western blot analysis as 
previously described [15, 37, 56]. Briefly, protein samples 
were separated in 10 % SDS polyacrylamide gel and were 
transferred to a polyvinylidene fluoride (PVDF) mem-
brane (Immobiloin®, Millipore, MA, USA). After the 
transfer, the membranes were blocked in 5 % milk con-
taining buffer (1X Tris buffered saline with Tween 20® 
[TBST]) for 30  min. In the following step, membranes 
were incubated with primary antibodies against human 
HuR, p27, cyclin D1, cyclin E, Bcl-2 (Santa Cruz Bio-
technology, Dallas TX, USA), Folic acid receptor-alpha 
(GeneTex Inc., Irvine, CA, USA), caspase-9 and PARP 
(Cell Signaling Technology Inc., Beverly, MA, USA), and 
beta-actin (Sigma-Aldrich, St. Louis, MO, USA), respec-
tively, in 5 % milk containing TBST. Protein bands were 
detected using appropriate horseradish peroxidase-
(HRP)-tagged secondary antibodies (Santa Cruz Bio-
technology) and an enhanced chemiluminescence kit 
(Thermo Scientific, MA, USA). Protein expression lev-
els were detected using a chemiluminescence imaging 
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system (Syngene, Frederick, MD, USA) and quantified 
using Gene tools (Syngene) software [37].
Cell migration assay
Cell migration assay was carried out as previously 
described [16, 57]. Briefly, H1299 cells (5  ×  104) were 
seeded in the upper chamber of the transwell (8 µm; BD 
Biosciences, Bedford, MA, USA), and were placed in 
individual wells (lower chamber) of six-well plates filled 
with 1  ml of serum-free RPMI-1640 medium. Cells 
were allowed to adhere for 24 h in the upper chamber, 
and were then transfected with C-FNP and HuR-FNP 
(100  nM siRNA dose) in serum-free medium. After 
6 h of transfection, the medium in the upper and lower 
chambers was replaced with 2 and 20 % serum-contain-
ing medium, respectively. The incubation continued 
until the inserts were removed and were processed at 24 
and 48  h, as previously described [16, 57]. The results 
were expressed as an average number of migrated 
cells per microscopic field. The experiments were per-
formed three times for reproducibility and statistical 
calculation.
Competitive inhibition studies
H1299 cells (1 ×  105  cells/well) were grown in six-well 
plates and were incubated for 1 h in RPMI-1640 medium 
containing excess of exogenous folic acid (1  mM). The 
cells were then transfected with HuR-FNP and were har-
vested after 24  h incubation. The harvested cells were 
used for cell viability measurements, western blot analy-
sis, and qRT-PCR assays.
In separate set of experiments, H1299 cells (1 ×  105/
well) were grown in RPMI medium containing 10 % FBS, 
with and without folic acid. After 24  h of incubation at 
37  °C, the cells were treated with HuR-FNP in serum-
free RPMI medium, with and without folic acid. After 
6  h incubation for transfection, medium was replaced 
with 2 % serum containing RPMI medium, either with or 
without folic acid. The cells were harvested at 24 h after 
HuR-FNP treatment and were used in cell viability, west-
ern blotting, and qRT-PCR assays.
Statistical analysis
Unless otherwise stated, all data are shown as 
mean  ±  standard deviation (SD). Univariate statisti-
cal significance was determined by one-way analysis of 
variance (ANOVA) with Tukey’s adjustment for pairwise 
comparisons. Differences between groups were obtained 
using a linear mixed effects model with Tukey’s adjust-
ment. A P value of less than 0.05 was considered sta-
tistically significant. SAS 9.2 software was used for the 
statistical analyses.
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